ACE2 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

ACE2 Inhibitors Market valued at USD 3,976.6 million in 2022 and is expected to grow at 4.9% CAGR over the forecast years 2024 – 2030. Angiotensin-converting enzyme 2 (ACE2) is an enzyme that can be found either attached to the membrane of cells (mACE2) in the intestines, kidney, testis, gallbladder, and heart or in a soluble form (sACE2). Both membrane-bound and soluble ACE2 are integral parts of the renin-angiotensin-aldosterone system (RAAS) that exists to keep the body's blood pressure in check. Soluble ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into angiotensin (a vasodilator) which in turn binds to MasR receptors creating localized vasodilation and hence decreases blood pressure. This decrease in blood pressure makes the entire process a promising drug target for treating cardiovascular diseases. This mechanism helps to reduce the buildup of cholesterol in the arteries and has the potential to reduce the risk of cardiovascular diseases, such as atherosclerosis and coronary artery disease.

Additionally, ACE2 Inhibitors may also lead to a decrease in LDL-C levels, which further contributes to their potential cardiovascular benefits. ACE2 Inhibitors are used for the treatment of viral infections, cancers, ulcerative colitis, colonic diseases, cardiovascular diseases, digestive system diseases, inflammatory bowel diseases, and intestinal diseases to name a few. Increased prevalence of heart diseases and hypertension due to changing lifestyles are the key drivers for the ACE2 Inhibitors market. For instance, according to the Centers for Disease Control and Prevention 2020, an estimated 5.5% of adults reported that they had been diagnosed with heart disease in the US. Moreover, to solve difficulties in therapy, a few market participants are developing innovative compounds. For instance, Celltrion’s Regkirona (Regdanvimab) for COVID-19 infections is under the various stages of clinical studies.

Key Market Developments:

• In August 2021, Regeneron in global collaboration with Roche’s REGEN-COV (Casirivimab/Imdevimab) revised by FDA for the emergency use authorization (EUA) for REGEN-COV (Casirivimab and Imdevimab), administered together) authorizing REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.
• In December 2021, Celltrion received the Therapeutic Goods Administration (TGA) grant for provisional approval for the use of Regdanvimab (Regkirona) in adult patients with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Drugs under the Pipeline for ACE2 Inhibitors:

• Pruxelutamide (GT0918)
• Ensovibep (MP0420)
• Regkirona (Regdanvimab)
• B38-CAP
• ACE2 CAR-NK Cells
• CG-Spikedown
• GL1001
• LY-Covmab
• NKG2D-ACE2 CAR-NK Cells

Clinical Activity and Developments of ACE2 Inhibitors:

Till July 2023, more than 10 companies have approximately 10 molecules targetting many digestive system diseases. For these molecules, more than 25 clinical trials are being conducted and the majority are in phase-2, and phase-3 clinical trials by players across the globe. For instance,

• In September 2022, Kintor Pharmaceuticals completed Phase I/Ib, an open-label, multicenter, dose-escalating study to evaluate the safety, tolerability, and pharmacokinetics of Pruxalutamide therapy in women with metastatic breast cancer.